BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8996155)

  • 21. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
    Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH; Bass D; Einhorn LH; Crawford J; Perez CA; Bartolucci A; Omura GA; Greco FA
    J Clin Oncol; 1993 Jul; 11(7):1223-9. PubMed ID: 8391064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.
    Bremnes RM; Sundstrøm S; Vilsvik J; Aasebø U;
    J Clin Oncol; 2001 Aug; 19(15):3532-8. PubMed ID: 11481360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapy for small cell lung cancer].
    Fukuoka M; Takada M; Masuda N; Furuse K; Saijo N; Ikegami H; Nishiwaki Y
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():225-31. PubMed ID: 7516450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung.
    Shaw EG; Frytak S; Eagan RT; Richardson RL; Creagan ET; Jett JR; Foote RL; Su JQ; Schaid DJ; Lee RE
    Am J Clin Oncol; 1996 Apr; 19(2):154-8. PubMed ID: 8610640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dose intensity chemotherapy in lung cancer].
    Takada M; Fukuoka M; Negoro S; Masuda N; Kudo S
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2005-12. PubMed ID: 1699498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: a pilot study of the Eastern Cooperative Oncology Group.
    Johnson DH; Turrisi AT; Chang AY; Blum R; Bonomi P; Ettinger D; Wagner H
    J Clin Oncol; 1993 May; 11(5):879-84. PubMed ID: 8387577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
    William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
    Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    Einhorn LH; Crawford J; Birch R; Omura G; Johnson DH; Greco FA
    J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
    J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
    Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
    Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
    Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.